{"id":30849,"date":"2025-01-21T16:39:44","date_gmt":"2025-01-21T11:09:44","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30849"},"modified":"2025-01-21T16:39:46","modified_gmt":"2025-01-21T11:09:46","slug":"pharma-news-for-amgen-novo-nordisk-boehringer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer","title":{"rendered":"FDA Approves LUMAKRAS with VECTIBIX for KRAS G12C-Mutated Colorectal Cancer; PYC Receives FDA Rare Pediatric Disease Designation for VP-001; Novo Nordisk Links High-Dose WEGOVY to Increased Weight Loss; FDA Rejects Atara\u2019s EBVALLO Due to Manufacturing Issues; Boehringer Faces Phase III Schizophrenia Fail and Legal Challenges"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1168ffdf068\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1168ffdf068\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\/#FDA_Approves_LUMAKRAS_and_VECTIBIX_for_KRAS_G12C-Mutated_Colorectal_Cancer\" >FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\/#FDA_Grants_PYC_Rare_Pediatric_Disease_Designation_for_VP-001_Drug_Program\" >FDA Grants PYC Rare Pediatric Disease Designation for VP-001 Drug Program<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\/#Novo_Nordisk_Links_High-Dose_WEGOVY_to_Greater_Weight_Loss_in_Phase_III_Trial\" >Novo Nordisk Links High-Dose WEGOVY to Greater Weight Loss in Phase III Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\/#FDA_Rejects_Ataras_Cell_Therapy_EBVALLO_Due_to_Manufacturing_Issues\" >FDA Rejects Atara\u2019s Cell Therapy EBVALLO Due to Manufacturing Issues<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\/#Boehringer_Faces_Phase_III_Schizophrenia_Fail_and_Legal_Challenges_from_HHS\" >Boehringer Faces Phase III Schizophrenia Fail and Legal Challenges from HHS<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-lumakras-and-vectibix-for-kras-g12c-mutated-colorectal-cancer\"><span class=\"ez-toc-section\" id=\"FDA_Approves_LUMAKRAS_and_VECTIBIX_for_KRAS_G12C-Mutated_Colorectal_Cancer\"><\/span>FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Amgen has secured FDA approval for <strong>LUMAKRAS (sotorasib)<\/strong> in combination with <strong>VECTIBIX (panitumumab)<\/strong> as a treatment for adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market\" class=\"ek-link\"><strong>KRAS G12C-mutated <\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market\" class=\"ek-link\">metastatic colorectal can<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market\" class=\"ek-link\"><strong>cer (mCRC)<\/strong><\/a> who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This approval is underpinned by the Phase III <strong>CodeBreaK 300 study<\/strong>, which showcased the combination&#8217;s ability to significantly enhance progression-free survival (PFS) compared to existing standards of care. The approval marks a significant step forward in providing targeted therapy for this specific patient population.<\/p>\n\n\n\n<p>The <strong>CodeBreaK 300 trial<\/strong> revealed that LUMAKRAS (960 mg daily) plus Vectibix delivered a median PFS of 5.6 months versus 2 months for standard care. Additionally, the combination achieved an overall response rate (ORR) of 26%, while the standard care yielded 0%. Safety profiles were consistent with historical data for both therapies, with common adverse effects including rash, diarrhea, and musculoskeletal pain. This innovative dual-targeted approach addresses a significant unmet need in the treatment of KRAS G12C-mutated mCRC.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;KRAS mutations are historically associated with worse outcomes, and standard treatment options have shown minimal benefit,&#8221; said <\/em><strong><em>Dr. Marwan G. Fakih<\/em><\/strong><em>, co-director of the Gastrointestinal Cancer Program at City of Hope. &#8220;This combination of sotorasib and panitumumab represents a much-needed treatment option, demonstrating superior progression-free survival in clinical trials.&#8221; <\/em><strong><em>Michael Sapienza<\/em><\/strong><em>, CEO of the Colorectal Cancer Alliance, added, &#8220;This breakthrough offers new hope to patients living with metastatic colorectal cancer and emphasizes the importance of innovation in precision medicine.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-grants-pyc-rare-pediatric-disease-designation-for-vp-001-drug-program\"><span class=\"ez-toc-section\" id=\"FDA_Grants_PYC_Rare_Pediatric_Disease_Designation_for_VP-001_Drug_Program\"><\/span>FDA Grants PYC Rare Pediatric Disease Designation for VP-001 Drug Program<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>PYC Therapeutics <\/strong>is making significant strides in precision therapies for genetic diseases with limited or no treatment options. Among its promising assets is <strong>VP-001<\/strong>, an investigational drug candidate targeting <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\" class=\"ek-link\">Retinit<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\" class=\"ek-link\"><strong>is Pigmentosa type 11 (RP11)<\/strong><\/a>, a rare childhood blinding eye disease caused by PRPF31 mutations. Currently in <strong>Phase I\/II studies<\/strong>, VP-001 is on track for a <strong>potentially registrational trial in 2025<\/strong>, underscoring the company\u2019s commitment to addressing unmet needs in rare genetic disorders.<\/p>\n\n\n\n<p>In a major milestone, <strong>VP-001 has been granted Rare Pediatric Disease (RPD) designation<\/strong> by the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for PRPF31-associated vision loss. The RPD program is designed to encourage the development of therapies for severe and rare conditions impacting children by offering potential benefits such as priority review vouchers. This designation validates PYC\u2019s innovative approach to tackling diseases like RP11 and paves the way for advancing VP-001 through clinical development.<\/p>\n\n\n\n<p>By focusing on precision therapies, PYC Therapeutics is creating hope for patients with rare genetic diseases, such as RP11, that currently lack effective treatments. With VP-001 advancing steadily, the company is poised to transform the therapeutic landscape for inherited retinal diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novo-nordisk-links-high-dose-wegovy-to-greater-weight-loss-in-phase-iii-trial\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_Links_High-Dose_WEGOVY_to_Greater_Weight_Loss_in_Phase_III_Trial\"><\/span>Novo Nordisk Links High-Dose WEGOVY to Greater Weight Loss in Phase III Trial<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Novo Nordisk<\/strong> has announced positive headline results from <strong>STEP UP<\/strong>, a Phase 3b trial within its global STEP program. The 72-week study assessed the efficacy and safety of <strong>subcutaneous semaglutide 7.2 mg<\/strong> compared to semaglutide 2.4 mg and placebo, administered weekly alongside lifestyle interventions. The trial involved <strong>1,407 <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\" class=\"ek-link\"><strong>adults with obes<\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\" class=\"ek-link\">i<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\" class=\"ek-link\"><strong>ty<\/strong><\/a> and achieved its <strong>primary endpoint<\/strong>, demonstrating <strong>statistically significant and superior weight loss<\/strong> with semaglutide 7.2 mg.<\/p>\n\n\n\n<p>Participants receiving <strong>semaglutide 7.2 mg<\/strong> achieved an average weight loss of <strong>20.7% from a baseline of 113 kg<\/strong>, compared to <strong>17.5% with semaglutide 2.4 mg<\/strong> and <strong>2.4% with placebo<\/strong> when adherence to treatment was assumed. Additionally, <strong>33.2%<\/strong> of those treated with semaglutide 7.2 mg achieved a weight loss of <strong>25% or more<\/strong>, surpassing the <strong>16.7%<\/strong> seen with semaglutide 2.4 mg and <strong>0%<\/strong> with placebo. The treatment policy estimand analysis showed weight reductions of <strong>18.7%<\/strong>, <strong>15.6%<\/strong>, and <strong>3.9%<\/strong> for semaglutide 7.2 mg, 2.4 mg, and placebo, respectively.<\/p>\n\n\n\n<p>Semaglutide 7.2 mg demonstrated a <strong>safe and well-tolerated profile<\/strong>, with gastrointestinal side effects being the most common, primarily mild to moderate and diminishing over time.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are very pleased to demonstrate <\/em><strong><em>20.7% weight loss<\/em><\/strong><em> and to see that <\/em><strong><em>33% of patients achieved more than 25% weight loss<\/em><\/strong><em> with semaglutide 7.2 mg, with a safety and tolerability profile comparable to semaglutide 2.4 mg,\u201d said Martin Holst Lange, executive vice president for Development at Novo Nordisk. He highlighted that these results further reinforce semaglutide&#8217;s clinical potential, building on the benefits established with <\/em><strong><em>Wegovy\u00ae<\/em><\/strong><em>, including <\/em><strong><em>cardiovascular risk reduction<\/em><\/strong><em> demonstrated in the SELECT trial.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-rejects-atara-s-cell-therapy-ebvallo-due-to-manufacturing-issues\"><span class=\"ez-toc-section\" id=\"FDA_Rejects_Ataras_Cell_Therapy_EBVALLO_Due_to_Manufacturing_Issues\"><\/span>FDA Rejects Atara\u2019s Cell Therapy EBVALLO Due to Manufacturing Issues<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Atara Biotherapeutics, Inc.<\/strong> has received a <strong>Complete Response Letter (CRL)<\/strong> from the <strong>FDA <\/strong>for its <strong>Biologics License Application (BLA)<\/strong> for <strong>EBVALLO\u2122 (tabelecleucel)<\/strong>. This investigational therapy is intended for adult and pediatric patients aged two years and older with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-market\" class=\"ek-link\">Epstein-<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-market\" class=\"ek-link\"><strong>Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)<\/strong><\/a> who have undergone at least one prior treatment, including an anti-CD20 therapy.<\/p>\n\n\n\n<p>The CRL pertains to observations made during a routine pre-license inspection of a <strong>third-party manufacturing facility<\/strong>. Importantly, no deficiencies were identified in <strong>EBVALLO\u2019s manufacturing process, clinical efficacy, or safety data<\/strong>, and the FDA has not requested additional clinical trials. Atara has committed to addressing these observations with its partner, Pierre Fabre Laboratories, and the third-party manufacturer, aiming for a resubmission that could potentially secure approval within six months.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are working closely with all stakeholders to address the FDA&#8217;s feedback and remain confident in the potential of <\/em><strong><em>EBVALLO<\/em><\/strong><em> to meet the significant unmet need for patients with <\/em><strong><em>EBV+ PTLD<\/em><\/strong><em>,\u201d said <\/em><strong><em>Cokey Nguyen, Ph.D.<\/em><\/strong><em>, President and CEO of Atara. The company plans to leverage the recent <\/em><strong><em>EMA approval of the FUJIFILM Diosynth Biotechnologies facility<\/em><\/strong><em> in Thousand Oaks, CA, as part of its global manufacturing strategy.&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Approved by the <strong>European Commission<\/strong> in December 2022, <strong>EBVALLO<\/strong> is an innovative, allogeneic <strong>Epstein-Barr virus-specific T-cell immunotherapy<\/strong> designed to eliminate EBV-infected cells. The U.S. BLA submission is based on the pivotal <strong>ALLELE study<\/strong>, which demonstrated a <strong>50% Objective Response Rate (ORR)<\/strong> and a favorable safety profile, reinforcing its potential as a <strong>first-in-class treatment<\/strong> for patients with this rare and life-threatening condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-boehringer-faces-phase-iii-schizophrenia-fail-and-legal-challenges-from-hhs\"><span class=\"ez-toc-section\" id=\"Boehringer_Faces_Phase_III_Schizophrenia_Fail_and_Legal_Challenges_from_HHS\"><\/span>Boehringer Faces Phase III Schizophrenia Fail and Legal Challenges from HHS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Boehringer Ingelheim<\/strong> has announced the discontinuation of its <strong>late-stage <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\" class=\"ek-link\"><strong>schizophrenia<\/strong><\/a><strong> program <\/strong>following <em>disappointing results <\/em>from the <strong>Phase III CONNEX trials<\/strong> for its investigational drug <strong>iclepertin<\/strong>. The trials, designed to evaluate the drug&#8217;s ability to improve cognitive and functional outcomes in schizophrenia patients, failed to meet their primary and secondary endpoints. At six months, iclepertin showed no significant improvements compared to placebo in any of the three studies.<\/p>\n\n\n\n<p>As a result, the company has decided to halt the planned long-term extension trial for iclepertin. While this marks a setback for Boehringer\u2019s efforts in schizophrenia, the company remains committed to advancing treatments for mood disorders. Boehringer highlighted its pipeline of over 20 investigational therapies in various stages of development, spanning schizophrenia, major depressive disorder, and other therapeutic areas.<\/p>\n\n\n\n<p>In a separate development, Boehringer continues to face challenges related to its legal dispute over the <strong>Inflation Reduction Act (IRA)<\/strong> and its drug price negotiation provisions. The company, alongside other pharmaceutical giants, has argued that the IRA\u2019s provisions amount to unconstitutional property seizure under the Fifth Amendment.<\/p>\n\n\n\n<p>However, a Connecticut court ruled in July 2024 that participation in the IRA\u2019s price negotiations is voluntary, with companies free to opt out if they deem it unprofitable. This week, the <strong>Department of Health and Human Services (HHS)<\/strong> reaffirmed this position in a legal filing, emphasizing that the program does not mandate property transfer and allows companies to withdraw from Medicare if they choose.<\/p>\n\n\n\n<p>While Boehringer has faced significant challenges on both clinical and legal fronts, the company continues to focus on its broader research initiatives and its innovative pipeline, aiming to deliver transformative treatments across therapeutic areas.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This approval is underpinned by the Phase III CodeBreaK 300 study, [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30850,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[204,20363,704,349,19000,18999,420,1173,639,5789,11777,22212,1519,22298],"industry":[17225],"therapeutic_areas":[17240,17227,17228,17244],"class_list":["post-30849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight","tag-epstein-barr-virus","tag-fda","tag-latest-pharma-news","tag-metastatic-colorectal-cancer","tag-metastatic-colorectal-cancer-market","tag-news","tag-obesity","tag-pharma-news","tag-recent-pharma-news","tag-retinitis-pigmentosa","tag-retinitis-pigmentosa-clinical-trials","tag-schizophrenia","tag-schizophrenia-drugs","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Amgen, Novo Nordisk, Boehringer<\/title>\n<meta name=\"description\" content=\"Amgen\u2019s LUMAKRAS &amp; VECTIBIX, PYC\u2019s VP-001, Novo Nordisk\u2019s WEGOVY, Atara\u2019s EBVALLO, Boehringer\u2019s Iclepertin\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Amgen, Novo Nordisk, Boehringer\" \/>\n<meta property=\"og:description\" content=\"Amgen\u2019s LUMAKRAS &amp; VECTIBIX, PYC\u2019s VP-001, Novo Nordisk\u2019s WEGOVY, Atara\u2019s EBVALLO, Boehringer\u2019s Iclepertin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T11:09:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-21T11:09:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Amgen, Novo Nordisk, Boehringer","description":"Amgen\u2019s LUMAKRAS & VECTIBIX, PYC\u2019s VP-001, Novo Nordisk\u2019s WEGOVY, Atara\u2019s EBVALLO, Boehringer\u2019s Iclepertin","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Amgen, Novo Nordisk, Boehringer","og_description":"Amgen\u2019s LUMAKRAS & VECTIBIX, PYC\u2019s VP-001, Novo Nordisk\u2019s WEGOVY, Atara\u2019s EBVALLO, Boehringer\u2019s Iclepertin","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-21T11:09:44+00:00","article_modified_time":"2025-01-21T11:09:46+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer","name":"Pharma News | Amgen, Novo Nordisk, Boehringer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer.png","datePublished":"2025-01-21T11:09:44+00:00","dateModified":"2025-01-21T11:09:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Amgen\u2019s LUMAKRAS & VECTIBIX, PYC\u2019s VP-001, Novo Nordisk\u2019s WEGOVY, Atara\u2019s EBVALLO, Boehringer\u2019s Iclepertin","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-novo-nordisk-boehringer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer.png","width":772,"height":482,"caption":"pharma-news-for-amgen-novo-nordisk-boehringer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/21163921\/pharma-news-for-amgen-novo-nordisk-boehringer-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epstein Barr virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Metastatic Colorectal Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Metastatic Colorectal Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Schizophrenia Drugs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Epstein Barr virus<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Metastatic Colorectal Cancer<\/span>","<span class=\"advgb-post-tax-term\">Metastatic Colorectal Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia Drugs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 21, 2025","modified":"Updated on Jan 21, 2025"},"absolute_dates_time":{"created":"Posted on Jan 21, 2025 4:39 pm","modified":"Updated on Jan 21, 2025 4:39 pm"},"featured_img_caption":"pharma-news-for-amgen-novo-nordisk-boehringer \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30849"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30849\/revisions"}],"predecessor-version":[{"id":30851,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30849\/revisions\/30851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30850"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30849"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30849"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}